Equity Profile

COGT

Cogent Biosciences, Inc.

Health CareBiotechnology$6.0B

May5Tue

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for patients with genetically defined diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

-$0.54

Revenue

Revenue figures are crucial for understanding the company's sales performance and market demand.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q1-2026 Earnings Preview

Context

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for patients with genetically defined diseases. Operating in the health care sector, Cogent's work is significant as it aims to address unmet medical needs through innovative treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In the last quarter, Cogent reported an EPS of -$0.64, which was worse than the expected -$0.55. The stock reacted negatively, dropping 0.19% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting another loss this quarter, with a consensus EPS of -$0.54. The lack of revenue projections indicates uncertainty about product sales.

Bull Case

If Cogent can narrow its losses or surprise with better-than-expected results, it could signal progress in its drug development pipeline, potentially boosting investor confidence.

Bear Case

Continued losses and lack of revenue could raise concerns about the company's financial stability and future growth prospects, leading to a negative market reaction.

Key Metrics to Watch

EPS

-$0.54

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$0M

Revenue figures are crucial for understanding the company's sales performance and market demand.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of -$0.54?

A better-than-expected EPS could indicate improvements in cost management or operational efficiency, which would be crucial for investor sentiment.

What updates can management provide on the development pipeline?

Insights into upcoming therapies and their potential market impact could significantly influence investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a smaller-than-expected EPS loss due to recent cost-cutting measures and operational efficiencies.

Supporting Evidence

The options market is pricing a 10.34% move, indicating expectations of volatility that may not align with the actual performance.

Cogent's historical performance shows that even with misses, the stock has often reacted positively in the following days.

Key Risk

If the EPS loss is less than -$0.54, it could challenge the current consensus view.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it reflects the company's ability to manage costs and progress in its drug development efforts.

Bull Confirmed If

A narrower EPS loss of -$0.46 or better would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.66 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.34%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±10.3% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

51.9%

Calls (42K)P/C Ratio: 0.06Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations with an EPS of -$0.46 or better, history suggests a potential stock increase of around 2.45%.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss with an EPS worse than -$0.66 could lead to a decline in stock price, with history suggesting an average drop of 3.44%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the drug development pipeline and potential timelines for upcoming trials.
2Details on cost management strategies and how they are impacting EPS.
3Insights into market demand for their therapies and any partnerships in development.
4Management's outlook on future revenue generation and product launches.
5Responses to analyst questions regarding competitive positioning in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Cogent Biosciences, Inc. is a biotechnology company focused on developing targeted therapies for patients with genetically defined diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

-$0.54

Revenue

Revenue figures are crucial for understanding the company's sales performance and market demand.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

COGT Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

-13.59%

Avg Stock Reaction

+3.32%

Last Quarter Recap

In the last quarter, Cogent reported an EPS of -$0.64, which was worse than the expected -$0.55. The stock reacted negatively, dropping 0.19% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are expecting another loss this quarter, with a consensus EPS of -$0.54. The lack of revenue projections indicates uncertainty about product sales.

Bull Case

If Cogent can narrow its losses or surprise with better-than-expected results, it could signal progress in its drug development pipeline, potentially boosting investor confidence.

Bear Case

Continued losses and lack of revenue could raise concerns about the company's financial stability and future growth prospects, leading to a negative market reaction.

Key Metrics to Watch

EPS

-$0.54

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$0M

Revenue figures are crucial for understanding the company's sales performance and market demand.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of -$0.54?

A better-than-expected EPS could indicate improvements in cost management or operational efficiency, which would be crucial for investor sentiment.

What updates can management provide on the development pipeline?

Insights into upcoming therapies and their potential market impact could significantly influence investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a smaller-than-expected EPS loss due to recent cost-cutting measures and operational efficiencies.

Supporting Evidence

The options market is pricing a 10.34% move, indicating expectations of volatility that may not align with the actual performance.

Cogent's historical performance shows that even with misses, the stock has often reacted positively in the following days.

Key Risk

If the EPS loss is less than -$0.54, it could challenge the current consensus view.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it reflects the company's ability to manage costs and progress in its drug development efforts.

Bull Confirmed If

A narrower EPS loss of -$0.46 or better would confirm the bull case.

Bear Confirmed If

An EPS loss greater than -$0.66 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.34%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±10.3% while COGT has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

51.9%

Calls (42K)P/C Ratio: 0.06Puts (21K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders adding

Institutional

103.29%

of float

Insider

0.29%

of float

Holders

362

institutions

Top Holders· as of Dec 2025

FMR, LLC
23,086,967 sh · $849.8M
14.22%
3.0%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Cogent beats expectations with an EPS of -$0.46 or better, history suggests a potential stock increase of around 2.45%.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.

Miss

A miss with an EPS worse than -$0.66 could lead to a decline in stock price, with history suggesting an average drop of 3.44%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the drug development pipeline and potential timelines for upcoming trials.
2Details on cost management strategies and how they are impacting EPS.
3Insights into market demand for their therapies and any partnerships in development.
4Management's outlook on future revenue generation and product launches.
5Responses to analyst questions regarding competitive positioning in the biotechnology sector.